This article is more than 5 years old. Information may no longer be current.
Four popular headlines to highlight Psoriasis Action Month
Click Here to Manage Email Alerts
Earlier this month, Healio Dermatology posted a compilation of eight popular reads to kickoff Psoriasis Action Month in psoriasis research, advocacy and FDA news.
Additionally, here are four of the biggest and most popular news updates in psoriasis to wind down August.
In the most popular article, a pilot study led to significant lesion improvement with crisaborole ointment 2% (Pfizer) in intertriginous, anogenital and facial psoriasis and may serve as a first-line therapy in these sensitive skin regions.
Crisaborole ointment possible first-line agent in psoriasis for thin, sensitive skin
The double-blind, randomized, vehicle-controlled study included 21 participants with intertriginous, anogenital or facial psoriasis who were randomly assigned 2:1 to crisaborole ointment 2% twice daily or vehicle ointment twice daily. Read more.
Taltz meets primary, secondary endpoints in head-to-head trial
The IXORA-R trial represents the first completed head-to-head trial between an interleukin-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. Read more.
Joint guidelines explore best practices in NB-UVB therapy for psoriasis
Healio Dermatology summarizes the joint findings on the risks and benefits of narrowband ultraviolet light B (NB-UVB) treatment. Read more.
“Phototherapy for the treatment of psoriasis has advanced significantly since the early days, nearly 100 years ago, of Goeckerman therapy, ie, the combination of crude coal tar plus broadband UVB (270-390 nm) in patient therapy,” Alan Menter, MD, chief of dermatology at Baylor Scott & White in Dallas, wrote in a perspective. Read more.
Some systemic psoriasis treatments may be associated with UTI risk
The use of cyclosporine, infliximab and anti-interleukin-17 in the treatment of psoriasis is associated with a higher risk for symptomatic urinary tract infection in women, according to a 10-year observational study. Read more.